Cover Image
市場調查報告書

第四型疱疹病毒(HHV-4)感染疾病 :開發中產品分析

Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484631
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
第四型疱疹病毒(HHV-4)感染疾病 :開發中產品分析 Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 74 Pages
簡介

Epstein-Barr virus(EBV)同時也稱作第四型人類疱疹病毒,是屬於皰疹病毒科的一種。同時也是最常見的人類病毒之一,一般是透過體液感染。EBV也會在性交時藉由精液、血液、輸血或器官移植傳染。症狀有疲勞感,發燒,喉嚨腫大,頭部淋巴結腫大,脾臟腫大,肝臟肥大,皮疹等。

本報告提供全球各國治療第四型疱疹病毒(HHV-4)感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

第四型疱疹病毒(HHV-4)感染疾病;概要

第四型疱疹病毒(HHV-4)感染疾病 - 治療藥的開發

  • 開發中產品 概要
  • 開發中產品:各企業
  • 開發中產品:各大學/研究機關
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Arno Therapeutics Inc
  • Cell Medica Ltd
  • Epiphany Biosciences Inc
  • Genocea Biosciences Inc
  • Omeros Corp
  • Savoy Pharmaceuticals Inc
  • Theravectys SA
  • Viracta Therapeutics Inc
  • Vironika LLC
  • ViroStatics srl

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9684IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape.

Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV spreads most commonly through bodily fluids. EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 7, 2, 1 and 2 molecules, respectively.

Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Epstein-Barr Virus (HHV-4) Infections - Overview
  • Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development
  • Advenchen Laboratories LLC
  • Arno Therapeutics Inc
  • bluebird bio Inc
  • Cell Medica Ltd
  • Epiphany Biosciences Inc
  • Genocea Biosciences Inc
  • Omeros Corp
  • TC BioPharm Ltd
  • Theravectys SA
  • Viracta Therapeutics Inc
  • Vironika LLC
  • ViroStatics srl
  • Epstein-Barr Virus (HHV-4) Infections - Drug Profiles
  • apatinib mesylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AR-12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • baltaleucel-T - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for EBV Associated PTLD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Infectious Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Systemic Lupus Erythematosus, Epstein-Barr Viral Infections and Multiple Sclerosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Viral Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy to Target Calcineurin A for EBV Associated Post Transplant Lymphoproliferative Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EBViNT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Epstein-Barr virus (virus like particle) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Epstein-Barr virus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GEN-007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MVA vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OmnImmune - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Prelym - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate ZTA for Epstein-Barr Virus (HHV-4) Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit EBNA1 for Epstein-Barr Virus Infections - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • valomaciclovir stearate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Viralym-M - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Viroprev - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VRx-3996 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Epstein-Barr Virus (HHV-4) Infections - Dormant Projects
  • Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones
  • Featured News & Press Releases
  • Dec 01, 2016: ViraCyte Announces Oral Presentations on Viralym-M Clinical Trial Results at the 58th American Society of Hematology Annual Meeting
  • Aug 18, 2016: Vironika Secures Phase I SBIR Funding From NIH To Develop Inhibitors For EBV Lytic Reactivation
  • Jun 02, 2014: Vironika Receives Phase II SBIR Grant From NIH To Continue The Development Of EBV Latency Inhibitors
  • Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Arno Therapeutics Inc, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by bluebird bio Inc, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cell Medica Ltd, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Epiphany Biosciences Inc, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Genocea Biosciences Inc, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Omeros Corp, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by TC BioPharm Ltd, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Theravectys SA, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Viracta Therapeutics Inc, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vironika LLC, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Pipeline by ViroStatics srl, H2 2017
  • Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top